PMID- 26871562
OWN - NLM
STAT- MEDLINE
DCOM- 20160729
LR  - 20160317
IS  - 1423-0232 (Electronic)
IS  - 0030-2414 (Linking)
VI  - 90
IP  - 3
DP  - 2016
TI  - Umbilical Cord Blood Transplantation Is a Feasible Rescue Therapeutic Option for 
      Patients Suffering from Graft Failure after Previous Hematopoietic Stem Cell 
      Transplantation.
PG  - 160-6
LID - 10.1159/000443767 [doi]
AB  - OBJECTIVE: Umbilical cord blood (UCB) is an important graft source for 
      hematopoietic stem cell transplantation (SCT). Due to less stringent human 
      leukocyte antigen (HLA) matching criteria compared to bone marrow or peripheral 
      blood stem cells, UCB enables patients lacking an HLA-matched donor to receive 
      potentially curative SCT. METHODS: We retrospectively analyzed the efficacy and 
      safety of UCB transplantation (UCBT) at our center. RESULTS: Between June 2009 
      and June 2015, 27 UCBT were performed in 25 patients. Reasons for the use of UCB 
      were lack of adequate related or unrelated stem cell donor (n = 20) and graft 
      failure after previous SCT (n = 7). Median time to neutrophil engraftment was 22 
      days. Four patients experienced primary graft failure. Thirteen patients 
      developed acute graft-versus-host disease (GVHD), whereupon 6 subsequently also 
      developed chronic GVHD. After a median follow-up time of 19 months, 9 patients 
      relapsed and 12 patients died. Cause of death was relapse in 8 and 
      transplant-related events in 4 patients. Median overall survival and 
      progression-free survival have not been reached yet. CONCLUSION: In our 
      experience, UCBT is an alternative graft source for patients lacking a suitable 
      related or unrelated donor and a feasible treatment option for patients 
      experiencing graft failure after previous SCT.
CI  - (c) 2016 S. Karger AG, Basel.
FAU - Bojic, Marija
AU  - Bojic M
AD  - Department of Medicine III, Clinical Division of Nephrology and Dialysis, Medical 
      University of Vienna, Vienna, Austria.
FAU - Worel, Nina
AU  - Worel N
FAU - Sperr, Wolfgang R
AU  - Sperr WR
FAU - Schellongowski, Peter
AU  - Schellongowski P
FAU - Wohlfarth, Philipp
AU  - Wohlfarth P
FAU - Schwarzinger, Ilse
AU  - Schwarzinger I
FAU - Mitterbauer-Hohendanner, Gerlinde
AU  - Mitterbauer-Hohendanner G
FAU - Fischer, Gottfried
AU  - Fischer G
FAU - Dieckmann, Karin Ute
AU  - Dieckmann KU
FAU - Lamm, Wolfgang
AU  - Lamm W
FAU - Leiner, Michael
AU  - Leiner M
FAU - Schulenburg, Axel
AU  - Schulenburg A
FAU - Mitterbauer, Margit
AU  - Mitterbauer M
FAU - Greinix, Hildegard T
AU  - Greinix HT
FAU - Kalhs, Peter
AU  - Kalhs P
FAU - Rabitsch, Werner
AU  - Rabitsch W
LA  - eng
PT  - Journal Article
DEP - 20160213
PL  - Switzerland
TA  - Oncology
JT  - Oncology
JID - 0135054
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Aged
MH  - Chronic Disease
MH  - Feasibility Studies
MH  - Female
MH  - Fetal Blood/*transplantation
MH  - Follow-Up Studies
MH  - Graft vs Host Disease/*etiology/*surgery
MH  - Hematologic Neoplasms/*surgery
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Salvage Therapy/*methods
MH  - Transplantation, Autologous
MH  - Transplantation, Homologous
MH  - Treatment Outcome
EDAT- 2016/02/13 06:00
MHDA- 2016/07/30 06:00
CRDT- 2016/02/13 06:00
PHST- 2015/12/26 00:00 [received]
PHST- 2015/12/28 00:00 [accepted]
PHST- 2016/02/13 06:00 [entrez]
PHST- 2016/02/13 06:00 [pubmed]
PHST- 2016/07/30 06:00 [medline]
AID - 000443767 [pii]
AID - 10.1159/000443767 [doi]
PST - ppublish
SO  - Oncology. 2016;90(3):160-6. doi: 10.1159/000443767. Epub 2016 Feb 13.